Proceedings of the Vertebrate Pest Conference

The compound bromethalin is described and characterized in terms of mode of action when used as a rodenticide. It is hypothesized that an antimetabolite which inhibits the conversion of bromethalin to its desmethylbromethalin metabolite could represent a potential treatment for bromethalin toxicosis. An ideal antimetabolite of bromethalin is described, and based on these considerations, aminophylline (theophylline ethylenediamine) was chosen as a potential antimetabolite. In lab trials, aminophylline was administered to rats given a lethal dose of bromethalin, but it was not effective in prolonging rat survival. However, it did result in mean survival time being increase to nearly double. Further studies aminophylline or similar drugs may results in identifying a suitable treatment for bromethalin-induced toxic syndrome.